CETSA Hsp90i - Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors

ABSTRACT: The goal of this project is to identify the drug target of XL888, an hsp90i used in clinical trial against melanoma

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Gianluca Maddalo  

LAB HEAD: Mathias Uhlen

PROVIDER: PXD005508 | Pride | 2018-02-13

REPOSITORIES: Pride